Aprogen submits AP209 trial documents to Kyung Hee University Hospital IRB

The osteoarthritis drug candidate will be tested in 16 knee osteoarthritis patients, with Aprogen aiming to start dosing within the year after South Korea IND clearance.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.